A Phase 4 interventional study of Digital Medicine System and Aripiprazole in Schizophrenia, Schizoaffective Disorder and First Episode Psychosis, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 5 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-07-16.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 96th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2018, is one of 56 in phase 4, and was the 111th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 85th largest by enrollment of the 111 interventional ones that give a count, is one of 3 that started in 2018, is one of 13 in phase 4, and was the 87th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use. The DMS is being developed as a healthcare management tool to precisely measure medication adherence and to potentially enhance adherence.
The advancements in the treatment of mental health patients with DMS will enable healthcare professionals to assess suboptimal adherence and make more informed treatment decisions. In addition to these improvements, it will also provide a platform for engagement between participants, healthcare professionals, and caregivers/support persons.
Participants who entered the trial were treated with one of the oral atypical antipsychotics defined in the trial (aripiprazole, olanzapine, quetiapine, or risperidone [though no participant took risperidone in this trial]). The treatment medication decision was determined by the healthcare professionals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
Device: Digital Medicine System · Drug: Aripiprazole
Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
Device: Digital Medicine System · Drug: Olanzapine
Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
Device: Digital Medicine System · Drug: Quetiapine
Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.
Device: Digital Medicine System · Drug: Risperidone
DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).
Dosage determined by the healthcare professionals.
Dosage determined by the healthcare professionals.
Dosage determined by the healthcare professionals.
Dosage determined by the healthcare professionals.
Percentage Of Days With Good Patch Coverage
The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (miniature ingestible event marker in tablet \[MIT\]). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Good patch coverage for a specific day was defined as having either at least 80% patch data available (80% of the day the patch was worn and data was collected as noted via the accelerometer channel) or the MIT was detected within the 24-hour period, for each day while the participant was in the trial. The percentage of days was calculated as the number of days with good patch coverage divided by the total number of trial days for each participant. Descriptive statistics were performed for this outcome measure.
Time frame: Up to 8 weeks
Participant Adherence
The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (MIT). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Participant adherence was measured as the detected MITs over the expected MITs ingested during the trial days with good patch coverage. The more the participant successfully engaged in a number of processes across the 8-week trial, the greater the measured adherence. Descriptive statistics were performed for this outcome measure.
Time frame: Up to 8 weeks
The trial enrolled participants with a confirmed clinical diagnosis of schizophrenia, schizoaffective disorder, or first episode psychosis.
| Milestone | Aripiprazole | Olanzapine | Quetiapine |
|---|---|---|---|
| Started | 18 | 20 | 6 |
| Received at least 1 dose of study drug | 18 | 19 | 6 |
| Completed | 8 | 14 | 2 |
| Not completed | 10 | 6 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 |
| Withdrew: Adverse event | 1 | 1 | 2 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 | 0 |
| Withdrew: Technical problems | 2 | 1 | 0 |
| Withdrew: Participant noncompliance | 1 | 1 | 0 |
The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (miniature ingestible event marker in tablet \[MIT\]). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Good patch coverage for a specific day was defined as having either at least 80% patch data available (80% of the day the patch was worn and data was collected as noted via the accelerometer channel) or the MIT was detected within the 24-hour period, for each day while the participant was in the trial. The percentage of days was calculated as the number of days with good patch coverage divided by the total number of trial days for each participant. Descriptive statistics were performed for this outcome measure.
| percentage of days | Schizophrenia | Schizoaffective Disorder | First Episode Psychosis | Total |
|---|---|---|---|---|
| Percentage Of Days With Good Patch Coverage | 64.34 ± 20.24 | 62.99 ± 37.68 | 62.51 ± 27.53 | 63.37 ± 26.60 |
The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (MIT). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Participant adherence was measured as the detected MITs over the expected MITs ingested during the trial days with good patch coverage. The more the participant successfully engaged in a number of processes across the 8-week trial, the greater the measured adherence. Descriptive statistics were performed for this outcome measure.
| percentage of MITs | Schizophrenia | Schizoaffective Disorder | First Episode Psychosis | Total |
|---|---|---|---|---|
| Participant Adherence | 88.94 ± 8.06 | 72.29 ± 25.65 | 91.04 ± 7.37 | 86.57 ± 14.47 |
Collected over Baseline to Week 24 (+ 7 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole | 0/18 (0%) | 0/18 (0%) | 4/18 (22.2%) |
| Olanzapine | 0/19 (0%) | 0/19 (0%) | 2/19 (10.5%) |
| Quetiapine | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Total | 0/43 (0%) | 0/43 (0%) | 9/43 (20.9%) |
| Event | Aripiprazole | Olanzapine | Quetiapine | Total |
|---|---|---|---|---|
| Medical device site irritationGeneral disorders | 4/18 | 2/19 | 3/6 | 9/43 |
Enrolled Population: All participants who signed an informed consent form and entered the trial (and only participants who met all of the inclusion criteria and none of the exclusion criteria).
| Age, Continuous(Years) | Aripiprazole | Olanzapine | Quetiapine | Total |
|---|---|---|---|---|
| Mean | 31.6 ± 9.6 | 38.0 ± 11.4 | 30.8 ± 8.8 | 34.4 ± 10.7 |
| Sex: Female, Male(Participants) | Aripiprazole | Olanzapine | Quetiapine | Total |
|---|---|---|---|---|
| Female | 8 | 4 | 3 | 15 |
| Male | 10 | 16 | 3 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Aripiprazole | Olanzapine | Quetiapine | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 17 | 18 | 5 | 40 |
| Unknown or Not Reported | 1 | 2 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Aripiprazole | Olanzapine | Quetiapine | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 0 | 8 |
| White | 14 | 15 | 6 | 35 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Disease Diagnosis(Participants) | Aripiprazole | Olanzapine | Quetiapine | Total |
|---|---|---|---|---|
| Schizophrenia | 5 | 13 | 0 | 18 |
| Schizoaffective Disorder | 4 | 4 | 2 | 10 |
| First Episode Psychosis | 9 | 3 | 4 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from May 2018 to primary completion in May 2019, 12 months.
Results were first posted in Jul 2020, 1 year 1 month after primary completion.
Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aripiprazole · Olanzapine · Quetiapine · Risperidone
Otsuka Pharmaceutical Development & Commercialization, Inc. →